(HS Mithoefer / Doblin 096211 2022) Emerging Psychedelic Treatments: Opportunities and Challenges
Tracking # 20-928525
Course overview
Media reports about psychedelics are now more likely to be about emerging therapeutic uses than about raves or drug busts. Are your clients asking you about them, are you curious about their potential to enliven psychotherapy? Clinical trials of MDMA and psilocybin as catalysts to psychotherapy are in final stages of FDA trials. Results show large treatment effects for PTSD, depression, and relationship satisfaction in couples. In this treatment model, the drugs are administered only a few times in a course of psychotherapy aimed at accessing the individual's own healing potential. Guided in this recording by the psychiatrist at the helm of the MDMA-assisted psychotherapy trials, you'll explore: The rationale for using drugs like MDMA as catalysts for psychotherapy How to understand the clinical trial results The MDMA-assisted psychotherapy process, illustrated with video clips The challenges of maintaining quality and equitable access as these treatments approach likely FDA approval
Subject areas
This course counts toward the state boards and subject areas below.
Florida Board of Clinical Social Work, Marriage and Family Therapy and Mental Health Counseling
Certified Master Social Worker
Licensed Clinical Social Worker
Licensed Marriage and Family Therapist
Licensed Mental Health Counselor
Florida Board of Nursing
Advanced Practice Registered Nurse
Licensed Practical Nurse
Registered Nurse
Florida Board of Psychology
Limited License Psychologist
Psychologist
Ohio Counselor, Social Worker and Marriage and Family Therapist Board
Licensed Independent Marriage and Family Therapist
Licensed Independent Social Worker
Licensed Professional Clinical Counselor
Licensed Professional Counselor
Licensed Social Worker
Marriage and Family Therapist
Registered Social Worker Assistant
Disclosure statements
Speaker Disclosures:
Financial: Dr. Michael Mithoefer has employment relationships with the Medical University of South Carolina and the Multidisciplinary Association for Psychedelic Studies. He has an ownership interest in Awakn Life Sciences and serves on the scientific advisory board. Dr. Mithoefer receives a speaking honorarium and recording royalties from PESI, Inc.
Non-financial: Dr. Michael Mithoefer is a fellow of the American Psychiatric Association.
Speaker Disclosures:
Financial: Richard Doblin has an employment relationship with Multidisciplinary Association for Psychedelic Studies, Inc. He receives a speaking honorarium and recording royalties from PESI, Inc. He has no relevant financial relationships with ineligible organizations.
Non-financial: Richard Doblin has no relevant non-financial relationships.